Assertio Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Assertio Therapeutics (ASRT) Misses Q3 EPS by 10c, Revenues Beat
November 6, 2020 6:17 AM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of ($0.09), $0.10 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $34.57 million versus the consensus estimate of $32.5 million.
Reported Net Product Sales of $34.3 MillionNon-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force IntegrationProvides Updated Outlook for Remainder of 2020We are proud of what we have achieved so far this year, as we... More
